Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160032 | 1.00 | EPHX1 (0.51) | EPHX1EPHX2MEN1KMT2APRCP | |
| SCHEMBL17437543 | 1.00 | EPHX1 (0.51) | EPHX1EPHX2MEN1KMT2APRCP | |
| SCHEMBL6337057 | 0.95 | EPHX1 (0.47) | EPHX1EPHX2MEN1KMT2ATSHR | |
| SCHEMBL15994667 | 0.80 | EPHX2 (0.49) | EPHX2 | |
| Hydrochloric Acid SCHEMBL9279520 | 0.79 | TSHR (0.56) | EPHX1EPHX2MEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL9279531 | 0.79 | TSHR (0.56) | EPHX1EPHX2MEN1KMT2ATSHR | |
| SCHEMBL17437601 | 0.76 | ALDH1A1 (0.51) | EPHX2PRCPTSHR | |
| SCHEMBL17437602 | 0.76 | ALDH1A1 (0.51) | EPHX2PRCPTSHR | |
| SCHEMBL5157950 | 0.75 | EPHX1 (0.61) | EPHX1EPHX2KMT2ATSHR | |
| SCHEMBL31462261 | 0.74 | ALDH1A1 (0.53) | EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | ABBOTT GMBH & CO., KG. (US) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | EPHX1 4175/4885EPHX2 4652/4885MEN1 609/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | EPHX1 4175/4885EPHX2 4652/4885MEN1 609/4885 |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | EPHX1 3852/4885EPHX2 4561/4885MEN1 459/4885 |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | CTRB1, CTRB2, BCKDK | EPHX1 2265/4885EPHX2 1654/4885MEN1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.